Skip to main content
. 2021 Jun 22;2021:6639366. doi: 10.1155/2021/6639366

Table 6.

Association between HPD and single or combination immunotherapy.

Monotherapy or combination Total (N = 377) Non-HPD (N = 339) HPD (N = 38) P value
Monotherapy 132 115 17 0.121
Dual-immunotherapy 8 6 2
Combine with chemotherapy/targeted therapy 237 218 19

HPD: hyperprogressive disease.